Hypothesis

The longevity benefits attributed to autophagy activation depend not on the magnitude of autophagic flux alone but on its precise temporal alignment with endogenous growth‑hormone (GH) secretory troughs. When autophagy is induced during GH lows, the cell executes a rationing program that prioritizes mitochondrial and proteostatic repair; when autophagy is activated outside these windows—by constant feeding, continuous GH/IGF‑1 replacement, or non‑pharmacologic agonists—the same flux fails to repair critical damage and may even exacerbate metabolic mismatch.

Mechanistic Rationale

• GH pulses create oscillating mTOR activity: peaks inhibit autophagy via PI3K‑Akt‑mTOR, troughs disinhibit ULK1 complex and permit autophagosome formation.
• During troughs, reduced ATP from lowered anabolism shifts NAD+/NADH ratios, activating SIRT1‑dependent deacetylation of LC3 and ATG proteins, which fine‑tunes selectivity toward damaged mitochondria (mitophagy) and protein aggregates.
• Interventions that raise autophagy without preserving this redox‑SIRT1 gate (e.g., rapamycin monotherapy) generate "non‑selective" bulk autophagy that recycles viable biosynthetic machinery, compromising repair efficiency.

Testable Predictions

1. In human subjects, time‑restricted feeding (TRF) that aligns feeding windows with the natural nocturnal GH nadir will increase LC3‑II/LC3‑I ratios and mitochondrial ROS reduction more than TRF misaligned with GH peaks.
2. Pharmacologic elevation of GH during troughs (using short‑acting GH secretagogues timed to troughs) will blunt the autophagic response to TRF, measurable by attenuated p62 degradation.
3. Continuous GH replacement in older adults will elevate basal LC3‑II but fail to improve mitophagy markers (e.g., reduced mitochondrial DNA copy number) and will correlate with increased serum IGF‑1 and mTORC1 activity.

Experimental Approach

• Cohort: 60 post‑menopausal women randomized to (a) TRF aligned with predicted GH trough (fasting 20:00–12:00), (b) TRF misaligned (fasting 08:00–20:00), (c) continuous feeding, each with or without nightly low‑dose GH antagonist.
• Readouts: Serial blood sampling for GH, IGF‑1, lactate; muscle biopsies at 0, 4, 8 h post‑fast for LC3‑II, p62, phosphorylated ULK1, mitochondrial respiration (Seahorse); PET‑MRI for mitochondrial ROS.
• Falsification: If aligned TRF does not produce superior mitophagy or metabolic improvement compared with misaligned TRF, the hypothesis is refuted.

Implications

This reframes autophagy activators as "chronotherapeutics" whose efficacy hinges on endocrine rhythmicity. It explains why broad mTOR inhibitors extend lifespan in model organisms but show mixed outcomes in humans: without respecting the pulsatile GH/IGF‑1 landscape, autophagy becomes a non‑targeted salvage operation rather than a precision rationing system.

1 2 3 4 5